ReviewAnnals of gastroenterological surgery2020
Evolving thresholds for liver transplantation in hepatocellular carcinoma: A Western experience.
Review in Annals of gastroenterological surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Liver transplantation for HCC with macrovascular invasion: A systematic review and meta-analysis of observational studies.JHEP reports : innovation in hepatology · 2026Article
- DPP4, a potential tumor biomarker, and tumor therapeutic target: review.Molecular biology reports · 2025Review
- Identification ofFrontiers in molecular biosciences · 2025Article
- Review
- Serial circulating tumor DNA profiling predicts tumor recurrence after liver transplantation for liver cancer.Hepatology international · 2024Article
- Biliary stenosis after liver transplant is not associated with cytomegalovirus infection.Translational gastroenterology and hepatology · 2024Article
- Deep Neural Network and Radiomics-based Magnetic Resonance Imaging System for Predicting Microvascular Invasion in Hepatocellular Carcinoma.Journal of Cancer · 2024Article
- Predictors of early and late hepatocellular carcinoma recurrence.World journal of gastroenterology · 2023Review
- Elevated expression of RAB3B plays important roles in chemoresistance and metastatic potential of hepatoma cells.BMC cancer · 2022Article
- A Meta-Analysis on the Rate of Hepatocellular Carcinoma Recurrence after Liver Transplant and Associations to Etiology, Alpha-Fetoprotein, Income and Ethnicity.Journal of clinical medicine · 2021Review
- Portal Vein Tumor Thrombosis and Hepatocellular Carcinoma - The Changing Tides.Journal of hepatocellular carcinoma · 2021Review
- Plasma MicroRNA Panel Predicts Early Tumor Recurrence in Patients with Hepatocellular Carcinoma after Liver Transplantation.Journal of Cancer · 2021Article
- Evolving thresholds for liver transplantation in hepatocellular carcinoma: A Western experience.Annals of gastroenterological surgery · 2020Review
- Patients treated with immune checkpoint inhibitors for HCC should not be considered for liver transplant.Clinical liver diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. Once considered an experimental treatment with dismal survival rates, liver transplantation for HCC entered a new era with the establishment of the Milan criteria over 20 years ago. In the modern post-Milan-criteria era, 5-year survival outcomes are now upwards of 70% in select patients. Liver transplantation (LT) is now considered the optimal treatment for patients with moderate to severe cirrhosis and HCC, and the rates of transplantation in the United States are continuing to rise. Several expanded selection criteria have been proposed for determining which patients with HCC should be candidates for undergoing LT with similar overall and recurrence-free survival rates to patients within the Milan criteria. There is also a growing experience with downstaging of patients who fall outside conventional LT criteria at the time of HCC diagnosis with the goal of tumor shrinkage via locoregional therapies to become a candidate for transplantation. The aim of this review article is to characterize the various patient selection criteria for LT, discuss balancing organ stewardship with outcome measures in HCC patients, present evidence on the role of downstaging for large tumors, and explore future directions of LT for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.